Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2011 1
2012 2
2013 3
2014 4
2015 2
2017 2
2018 3
2020 1
2021 3
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, Landschulz W, Haupt A, Frias JP. Bue-Valleskey JM, et al. Among authors: chigutsa e. Diabetes Care. 2023 May 1;46(5):1060-1067. doi: 10.2337/dc22-2396. Diabetes Care. 2023. PMID: 36944059 Free PMC article. Clinical Trial.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I, Willis BA, Chua L, Chow K, Ernest CS 2nd, Wang J, Shcherbinin S, Sims JR, Chigutsa E. Gueorguieva I, et al. Among authors: chigutsa e. Alzheimers Dement (N Y). 2023 Jun 28;9(2):e12404. doi: 10.1002/trc2.12404. eCollection 2023 Apr-Jun. Alzheimers Dement (N Y). 2023. PMID: 37388759 Free PMC article.
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
Frias J, Chien J, Zhang Q, Chigutsa E, Landschulz W, Syring K, Wullenweber P, Haupt A, Kazda C. Frias J, et al. Among authors: chigutsa e. Lancet Diabetes Endocrinol. 2023 Mar;11(3):158-168. doi: 10.1016/S2213-8587(22)00388-6. Epub 2023 Feb 6. Lancet Diabetes Endocrinol. 2023. PMID: 36758572 Clinical Trial.
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
Chen P, Datta G, Grace Li Y, Chien J, Price K, Chigutsa E, Brown-Augsburger P, Poorbaugh J, Fill J, Benschop RJ, Rouphael N, Kay A, Mulligan MJ, Saxena A, Fischer WA, Dougan M, Klekotka P, Nirula A, Benson C. Chen P, et al. Among authors: chigutsa e. Clin Pharmacol Ther. 2021 Dec;110(6):1467-1477. doi: 10.1002/cpt.2405. Epub 2021 Oct 16. Clin Pharmacol Ther. 2021. PMID: 34455583 Free PMC article. Clinical Trial.
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
Ernest CS 2nd, Chien JY, Patel DR, Chigutsa E. Ernest CS 2nd, et al. Among authors: chigutsa e. CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):721-730. doi: 10.1002/psp4.12784. Epub 2022 Apr 5. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35289125 Free PMC article. Clinical Trial.
25 results